Broadening the Treatment Horizon: Examining the Expanding Roles of New Therapies in Epilepsy Management
Program DescriptionRecent advances in the understanding of the genetics of epilepsy have led to new insights that stand to significantly improve treatment for individual patient presentations and needs.
Category
Format
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Out of the Dark, Into the Light: Illuminating Modern Strategies for the Detection and Treatment of Bipolar Depression
OverviewUp to 80% of patients with bipolar disorder (BD) initially present with depression. However, without experience of or insight into their mania, these patients are easily misdiagnosed with major depressive disorder (MDD) or other psychiatric conditions.
Category
Format
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Thinking Through ARIA: A Case-Based Exploration of Recognition, Evaluation, and Reporting of Novel Imaging Events of Alzheimer's Therapeutics
Program Description
Category
Format
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Individualizing Narcolepsy: Using Clinical Evidence and Patient Factors to Improve Diagnosis and Optimize Therapeutic Management
Program DescriptionSleep experts Drs. Lynn Marie Trotti, Asim Roy, and Anne Marie Morse offer a comprehensive approach to narcolepsy treatment, embracing recent pharmacological advancements (e.g., pitolisant, solriamfetol, low sodium oxybate [LXB], once nightly sodium oxybate [ON-SXB]).
Category
Format
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Stronger Together: Leveraging Evidence-Based Patient Collaboration and Treatment Strategies to Streamline Success in Multiple Sclerosis
Program DescriptionWith the variety of possible risk factors, presentations, impacts, and preferences among individual patients with multiple sclerosis (MS), it has been well-established that every case of MS is unique.
Category
Format
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Unlocking the Alzheimer’s Brain: How Radiological Tools and Biomarkers Hold the Key to Early Diagnosis and Decision-Making
Program DescriptionThe age of disease-modifying therapy in Alzheimer’s disease (AD) is now a reality with one amyloid beta targeting therapy (ATT) approved and another under regulatory review.
Category
Format
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Pages